MHRA Class 4 Medicines Defect Information: Vyvgart 1000 mg solution for injection (Argenx BV)

MHRA Class 4 Medicines Defect Information: Vyvgart 1000 mg solution for injection (Argenx BV)

Drug alert number: EL (24)A/63

Date issued: 19 December 2024

The Medicines and Health products Regulatory Agency (MHRA) has issued a class 4 medicines defect information notice for: Vyvgart 1000 mg solution for injection (Argenx BV)

DMRC reference number: DMRC-34131563

Company name:Argenx BV

Product name:Vyvgart 1000 mg solution for injection, PLGB 47104/0005

SNOMED Code: 42703811000001101

Active Pharmaceutical Ingredient: efgartigimod alfa

Brief description of the problem

Argenx BV have informed MHRA that the Patient Information Leaflet (PIL) in the affected packs incorrectly contains reference to two subcutaneous injection sites (abdomen and thigh) at Step 20 of the instructions. The correct PIL, approved as part of the GB marketing authorisation, only contains reference to one subcutaneous injection site (abdomen).

Advice for healthcare professionals

Healthcare professionals should only administer the product via the abdomen. This is described in the approved PIL and can be accessed electronically at VYVGART 1000 mg solution for injection – Patient Information Leaflet (PIL) – (emc).

Any healthcare professionals providing the affected batches to patients for self-administration should advise patients to administer via the abdomen.

View full alert here.

Advice for patients

Patients should continue to take medicines from these batches as prescribed by your healthcare professional. This does not affect the quality of the product. Any patient who has received self-administration training should administer the product via the abdomen. This is described in the approved (correct) PIL and can be accessed electronically at VYVGART 1000 mg solution for injection – Patient Information Leaflet (PIL) – (emc).

If you have any concerns about the information provided with your medicine, please speak with your pharmacy team in the first instance. If you have concerns about a medicine, you may be using, please contact your healthcare professional.

Patients who experience adverse reactions or have any questions about the medication, should seek medical attention. Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme.

Further Information

For medical information enquiries please contact ukmedinfo@argenx.com or +44 (0)20 4532 4016.

For stock control enquiries please contact rpi@argenx.com or +44 (0)7801 748936.